TY - JOUR
T1 - Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study
AU - Aguilar-Salinas, Carlos A.
AU - Gómez-Pérez, Francisco J.
AU - Posadas-Romero, Carlos
AU - Vázquez-Chávez, Cuauhtémoc
AU - Meaney, Eduardo
AU - Gulías-Herrero, Alfonso
AU - Guillén, Luz E.
AU - Alvarado Vega, Alma
AU - Mendoza Pérez, Enrique
AU - Eduardo Romero-Nava, Luis
AU - Angélica Gómez-Díaz, Rita
AU - Salinas-Orozco, Saúl
AU - Moguel, Rafael
AU - Novoa, Germán
PY - 2000/10
Y1 - 2000/10
N2 - Hyperlipidemia is common in type 2 diabetic patients and is an independent risk factor for cardiovascular disease. The aim of this trial was to evaluate the efficacy and safety of once-daily atorvastatin 10-80 mg for the treatment of hyperlipidemia in type 2 diabetics with plasma low-density lipoprotein cholesterol (LDL-C) levels exceeding 3.4 mmol/l (130 mg/dl). One hundred and two patients met the study criteria and received 10 mg/day atorvastatin. Patients who reached the target LDL-C level of ≤2.6 mmol/l (100 mg/dl) maintained the same dosage regimen until they had completed 16 weeks of treatment. Patients not reaching the target LDL-C underwent dose titration to atorvastatin 20, 40 and 80 mg/day at Weeks 4, 8 and 12, respectively. All 88 patients who completed the study attained target LDL-C levels and 52 (59%) of patients achieved the target goal at the starting dose of atorvastatin 10 mg/day. In this group the differences between baseline and post-treatment values for LDL-C were 4.3±0.7 mmol/l (166±26 mg/dl) versus 2.2±0.4 mmol/l (87±14 mg/dl) (P<0.0001), respectively, a decrease of 47%. Similar trends were observed for total cholesterol, triglycerides, very low-density lipoprotein cholesterol and apolipoprotein B levels. The safety profile of atorvastatin in these patients was highly favorable and similar to those reported with other statins. Only one patient withdrew due to a possible drug-related adverse event. These data confirm the marked efficacy and safety of atorvastatin in type 2 diabetic patients with hyperlipidemia and the efficacy of atorvastatin 10 mg in helping patients attain their LDL-C goal. Copyright (C) 2000 Elsevier Science Ireland Ltd.
AB - Hyperlipidemia is common in type 2 diabetic patients and is an independent risk factor for cardiovascular disease. The aim of this trial was to evaluate the efficacy and safety of once-daily atorvastatin 10-80 mg for the treatment of hyperlipidemia in type 2 diabetics with plasma low-density lipoprotein cholesterol (LDL-C) levels exceeding 3.4 mmol/l (130 mg/dl). One hundred and two patients met the study criteria and received 10 mg/day atorvastatin. Patients who reached the target LDL-C level of ≤2.6 mmol/l (100 mg/dl) maintained the same dosage regimen until they had completed 16 weeks of treatment. Patients not reaching the target LDL-C underwent dose titration to atorvastatin 20, 40 and 80 mg/day at Weeks 4, 8 and 12, respectively. All 88 patients who completed the study attained target LDL-C levels and 52 (59%) of patients achieved the target goal at the starting dose of atorvastatin 10 mg/day. In this group the differences between baseline and post-treatment values for LDL-C were 4.3±0.7 mmol/l (166±26 mg/dl) versus 2.2±0.4 mmol/l (87±14 mg/dl) (P<0.0001), respectively, a decrease of 47%. Similar trends were observed for total cholesterol, triglycerides, very low-density lipoprotein cholesterol and apolipoprotein B levels. The safety profile of atorvastatin in these patients was highly favorable and similar to those reported with other statins. Only one patient withdrew due to a possible drug-related adverse event. These data confirm the marked efficacy and safety of atorvastatin in type 2 diabetic patients with hyperlipidemia and the efficacy of atorvastatin 10 mg in helping patients attain their LDL-C goal. Copyright (C) 2000 Elsevier Science Ireland Ltd.
KW - Atorvastatin
KW - Hypercholesterolemia
KW - Low-density lipoprotein cholesterol
KW - Triglyceride
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=17144457592&partnerID=8YFLogxK
U2 - 10.1016/S0021-9150(99)00502-X
DO - 10.1016/S0021-9150(99)00502-X
M3 - Artículo
SN - 0021-9150
VL - 152
SP - 489
EP - 496
JO - Atherosclerosis
JF - Atherosclerosis
IS - 2
ER -